董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Walter V. Klemp | 男 | Chairman of the Board,Director,Chief Executive Officer and President | 66 | 134.60万美元 | 207.08 | 2026-08-19 |
| Robert E. George | 男 | Independent Director | 75 | 12.67万美元 | 0.07 | 2026-08-19 |
| Michael D. Cannon | 男 | Director | 80 | 12.02万美元 | 0.06 | 2026-08-19 |
| Elizabeth A. Cermak | 女 | Independent Director | 68 | 11.52万美元 | 0.06 | 2026-08-19 |
| John M. Climaco | 男 | Independent Director | 57 | 13.52万美元 | 0.06 | 2026-08-19 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Walter V. Klemp | 男 | Chairman of the Board,Director,Chief Executive Officer and President | 66 | 134.60万美元 | 207.08 | 2026-08-19 |
| Donald Picker | 男 | Chief Scientific Officer | 80 | 62.29万美元 | 69.55 | 2026-08-19 |
| Jonathan P. Foster | 男 | Chief Financial Officer and Executive Vice President | 62 | 90.73万美元 | 128.82 | 2026-08-19 |
董事简历
中英对照 | 中文 | 英文- Walter V. Klemp
-
Walter V. Klemp，公司联合创始人，自2015年7月起担任董事会主席兼首席执行官，自2017年8月起担任总裁。Klepp先生还自2022年1月起担任Autonomix Medical，Inc.（纳斯达克：AMIX）董事会执行主席。从2018年7月到2021年12月，Klepp先生在Soliton, Inc.的董事会担任执行主席，该公司是一家医疗器械公司，专注于为Moleculin Biotech Biotech，Inc. e开发美学新技术。2021年12月，Soliton，Inc.被AbbVie，Inc.收购。2011年11月至2018年7月，Klemp先生担任Soliton的首席执行官。Klemp先生于2004年至2011年4月担任Zeno Corporation的总裁兼首席执行官，在那里他从概念到FDA批准和市场启动，开发和销售皮肤病设备和药物。从1987年到2000年，Klemp先生担任Drypers Corporation的首席执行官和董事长，该公司是一家上市的跨国消费品公司，在INC 500美国增长最快公司名单上排名第一。
Walter V. Klemp is a co founder of Moleculin Biotech, Inc., a clinical stage pharmaceutical company, and has served as its Chairman of the Board and Chief Executive Officer since July 2015 and as president since August 2017. From July 2018 until December 2021, Mr. Klemp served as Executive Chairman on the Board of Directors of Soliton, Inc., a medical device company focused on developing new technology for use in aesthetics. In December 2021 Soliton, Inc. was acquired by AbbVie, Inc. From November 2011 to July 2018, Mr. Klemp served as Chief Executive Officer of Soliton. Mr. Klemp served as President and Chief Executive Officer of Zeno Corporation from 2004 to April 2011, where he developed and marketed dermatology devices and drugs from concept through FDA approval and market launch. From 1987 to 2000, Mr. Klemp served as Chief Executive Officer and Chairman of Drypers Corporation, a publicly traded multinational consumer products company that was listed as #1 on the INC 500 List of America's Fastest Growing Companies. - Walter V. Klemp，公司联合创始人，自2015年7月起担任董事会主席兼首席执行官，自2017年8月起担任总裁。Klepp先生还自2022年1月起担任Autonomix Medical，Inc.（纳斯达克：AMIX）董事会执行主席。从2018年7月到2021年12月，Klepp先生在Soliton, Inc.的董事会担任执行主席，该公司是一家医疗器械公司，专注于为Moleculin Biotech Biotech，Inc. e开发美学新技术。2021年12月，Soliton，Inc.被AbbVie，Inc.收购。2011年11月至2018年7月，Klemp先生担任Soliton的首席执行官。Klemp先生于2004年至2011年4月担任Zeno Corporation的总裁兼首席执行官，在那里他从概念到FDA批准和市场启动，开发和销售皮肤病设备和药物。从1987年到2000年，Klemp先生担任Drypers Corporation的首席执行官和董事长，该公司是一家上市的跨国消费品公司，在INC 500美国增长最快公司名单上排名第一。
- Walter V. Klemp is a co founder of Moleculin Biotech, Inc., a clinical stage pharmaceutical company, and has served as its Chairman of the Board and Chief Executive Officer since July 2015 and as president since August 2017. From July 2018 until December 2021, Mr. Klemp served as Executive Chairman on the Board of Directors of Soliton, Inc., a medical device company focused on developing new technology for use in aesthetics. In December 2021 Soliton, Inc. was acquired by AbbVie, Inc. From November 2011 to July 2018, Mr. Klemp served as Chief Executive Officer of Soliton. Mr. Klemp served as President and Chief Executive Officer of Zeno Corporation from 2004 to April 2011, where he developed and marketed dermatology devices and drugs from concept through FDA approval and market launch. From 1987 to 2000, Mr. Klemp served as Chief Executive Officer and Chairman of Drypers Corporation, a publicly traded multinational consumer products company that was listed as #1 on the INC 500 List of America's Fastest Growing Companies.
- Robert E. George
-
Robert E. George于首次公开发行股票时加入公司董事会。他曾是普华永道（PWC）国际会计师事务所的合伙人长达27年，直到2010年，他的客户服务领域包括医疗保健等。乔治先生目前担任休斯顿得克萨斯大学健康科学中心审计委员会主席，并从2011年至2024年担任得克萨斯大学奥斯汀麦库姆斯商业会计研究生院教员。乔治先生拥有北德克萨斯大学会计学学士学位（优等生）。
Robert E. George joined the company's Board of Directors upon IPO. He was a partner with the international accounting firm of PricewaterhouseCoopers (PWC) for 27 years until 2010, where his client service sectors included healthcare, among others. Mr. George currently serves as Chairman of the Audit Committee for The University of Texas Health Science Center at Houston and, from 2011 2024, was a member of The University of Texas at Austin McCombs Graduate School of Business accounting faculty. Mr. George has a B.B.A. Accounting (cum laude) from the University of North Texas. - Robert E. George于首次公开发行股票时加入公司董事会。他曾是普华永道（PWC）国际会计师事务所的合伙人长达27年，直到2010年，他的客户服务领域包括医疗保健等。乔治先生目前担任休斯顿得克萨斯大学健康科学中心审计委员会主席，并从2011年至2024年担任得克萨斯大学奥斯汀麦库姆斯商业会计研究生院教员。乔治先生拥有北德克萨斯大学会计学学士学位（优等生）。
- Robert E. George joined the company's Board of Directors upon IPO. He was a partner with the international accounting firm of PricewaterhouseCoopers (PWC) for 27 years until 2010, where his client service sectors included healthcare, among others. Mr. George currently serves as Chairman of the Audit Committee for The University of Texas Health Science Center at Houston and, from 2011 2024, was a member of The University of Texas at Austin McCombs Graduate School of Business accounting faculty. Mr. George has a B.B.A. Accounting (cum laude) from the University of North Texas.
- Michael D. Cannon
-
Michael D. Cannon于首次公开发行股票时加入公司董事会。1997年至2004年期间，Cannon先生担任美国上市制药公司SICOR，Inc.的首席科学官、执行副总裁和董事，直到该公司被梯瓦制药公司收购。SICOR专注于仿制药成品剂量注射药物、活性药物成分和生物仿制药。在SICOR期间，他监督了生物业务的收购和发展，包括发起和管理国际合作伙伴关系，以及蛋白质制造设施的设计、建设和许可。从2005年7月到2009年12月，Cannon先生是Trevi Health Ventures LP的科学顾问委员会成员，这是一家专门从事医疗保健投资的纽约投资基金。从2005年5月到2011年12月，Cannon先生是为评估和执行医疗保健部门知识产权的初步开发而成立的私人合伙企业的合伙人。自2005年以来，坎农先生一直担任多家私营公司的董事会成员。坎农目前在三家私营生物技术公司的董事会任职。他此前曾在Athenex, Inc.的董事会任职，该公司是一家在纳斯达克上市的上市公司。坎农先生拥有福特汉姆学院的化学学位。
Michael D. Cannon joined the company's Board of Directors upon IPO. Between 1997 and 2004, Mr. Cannon was the Chief Science Officer, EVP and a Director of SICOR, Inc., a U.S. public pharmaceutical company, until its acquisition by Teva Pharmaceutical Industries, Inc. SICOR focused on generic finished dosage injectable pharmaceuticals, active pharmaceutical ingredients and biogenerics. While at SICOR, he oversaw the acquisition and development of the biological business, including initiation and management of international partnerships, as well as on the design, construction, and licensure of protein manufacturing facilities. From July 2005 to December 2009, Mr. Cannon was a member of the scientific advisory board of Trevi Health Ventures LP, a New York investment fund specializing in health care investments. From May 2005 until December 2011, Mr. Cannon was a partner in a private partnership formed to evaluate and perform preliminary development of intellectual property in the healthcare sector. Since 2005, Mr. Cannon has served as a board member for several private companies. Mr. Cannon currently serves on the boards of directors of three privately held biotech companies. He previously served on the board of directors of Athenex, Inc., a public company traded on the Nasdaq. Mr. Cannon has a degree in chemistry from Fordham College. - Michael D. Cannon于首次公开发行股票时加入公司董事会。1997年至2004年期间，Cannon先生担任美国上市制药公司SICOR，Inc.的首席科学官、执行副总裁和董事，直到该公司被梯瓦制药公司收购。SICOR专注于仿制药成品剂量注射药物、活性药物成分和生物仿制药。在SICOR期间，他监督了生物业务的收购和发展，包括发起和管理国际合作伙伴关系，以及蛋白质制造设施的设计、建设和许可。从2005年7月到2009年12月，Cannon先生是Trevi Health Ventures LP的科学顾问委员会成员，这是一家专门从事医疗保健投资的纽约投资基金。从2005年5月到2011年12月，Cannon先生是为评估和执行医疗保健部门知识产权的初步开发而成立的私人合伙企业的合伙人。自2005年以来，坎农先生一直担任多家私营公司的董事会成员。坎农目前在三家私营生物技术公司的董事会任职。他此前曾在Athenex, Inc.的董事会任职，该公司是一家在纳斯达克上市的上市公司。坎农先生拥有福特汉姆学院的化学学位。
- Michael D. Cannon joined the company's Board of Directors upon IPO. Between 1997 and 2004, Mr. Cannon was the Chief Science Officer, EVP and a Director of SICOR, Inc., a U.S. public pharmaceutical company, until its acquisition by Teva Pharmaceutical Industries, Inc. SICOR focused on generic finished dosage injectable pharmaceuticals, active pharmaceutical ingredients and biogenerics. While at SICOR, he oversaw the acquisition and development of the biological business, including initiation and management of international partnerships, as well as on the design, construction, and licensure of protein manufacturing facilities. From July 2005 to December 2009, Mr. Cannon was a member of the scientific advisory board of Trevi Health Ventures LP, a New York investment fund specializing in health care investments. From May 2005 until December 2011, Mr. Cannon was a partner in a private partnership formed to evaluate and perform preliminary development of intellectual property in the healthcare sector. Since 2005, Mr. Cannon has served as a board member for several private companies. Mr. Cannon currently serves on the boards of directors of three privately held biotech companies. He previously served on the board of directors of Athenex, Inc., a public company traded on the Nasdaq. Mr. Cannon has a degree in chemistry from Fordham College.
- Elizabeth A. Cermak
-
Elizabeth A. Cermak，自2009年加入POZEN担任执行副总裁和首席商务官。在加入POZEN之前，即2006年她担任Johnson and Johnson的消费者健康部门的世界范围内副总裁。2005年她是McNeil Consumer and Specialty股份有限公司业务拓展副总裁，2003-2005年是Ortho-McNeil Pharmaceuticals股份有限公司女性健康特许副总裁。她在医疗保健行业花了25年的时间并带领许多营销和销售组织。她拥有Drexel大学（位于宾夕法尼亚州费城（Philadelphia, PA））财务专业的工商管理硕士学位和Franklin and Marshall学院（位于宾夕法尼亚州费城（Philadelphia, PA））会计学士学位。
Elizabeth A. Cermak joined Moleculin Biotech, Inc.'s Board of Directors in October 2020. Ms. Cermak has held numerous board positions in the healthcare space, including most recently at Clarus Therapeutics, Inc., where she served as an Independent Board Director. In addition, Ms. Cermak was also formerly an Independent Board Director at Neurana Pharmaceuticals, QUE Oncology and SteadyMed Therapeutics. From 2009 to 2013, Ms. Cermak was the Chief Commercial Officer and Executive Vice President at POZEN, now Aralez Pharmaceuticals. As Chief Commercial Officer at POZEN, Ms. Cermak developed the commercial strategy and launch Plans for the Company's first self marketed product, and signed licensing deals with Johnson & Johnson, Desitin, and Sanofi. Prior to joining POZEN, Ms. Cermak worked at Johnson & Johnson for 25 years, serving most recently as World Wide Vice President Personal Products Franchise and Vice President Professional Sales & Marketing, and leading the US Women's Health Pharmaceutical business. - Elizabeth A. Cermak，自2009年加入POZEN担任执行副总裁和首席商务官。在加入POZEN之前，即2006年她担任Johnson and Johnson的消费者健康部门的世界范围内副总裁。2005年她是McNeil Consumer and Specialty股份有限公司业务拓展副总裁，2003-2005年是Ortho-McNeil Pharmaceuticals股份有限公司女性健康特许副总裁。她在医疗保健行业花了25年的时间并带领许多营销和销售组织。她拥有Drexel大学（位于宾夕法尼亚州费城（Philadelphia, PA））财务专业的工商管理硕士学位和Franklin and Marshall学院（位于宾夕法尼亚州费城（Philadelphia, PA））会计学士学位。
- Elizabeth A. Cermak joined Moleculin Biotech, Inc.'s Board of Directors in October 2020. Ms. Cermak has held numerous board positions in the healthcare space, including most recently at Clarus Therapeutics, Inc., where she served as an Independent Board Director. In addition, Ms. Cermak was also formerly an Independent Board Director at Neurana Pharmaceuticals, QUE Oncology and SteadyMed Therapeutics. From 2009 to 2013, Ms. Cermak was the Chief Commercial Officer and Executive Vice President at POZEN, now Aralez Pharmaceuticals. As Chief Commercial Officer at POZEN, Ms. Cermak developed the commercial strategy and launch Plans for the Company's first self marketed product, and signed licensing deals with Johnson & Johnson, Desitin, and Sanofi. Prior to joining POZEN, Ms. Cermak worked at Johnson & Johnson for 25 years, serving most recently as World Wide Vice President Personal Products Franchise and Vice President Professional Sales & Marketing, and leading the US Women's Health Pharmaceutical business.
- John M. Climaco
-
John M. Climaco， 他是一名法律博士，也是一位经验丰富而且成就突出的企业行政管理人员、董事和律师，并且具备15年在上市公司和私营企业任职的企业管理和企业战略经验。自2012年12月，他在Digirad 公司担任董事。自2013年12月，他在PDI公司任职。PDI公司是一家外包销售和营销的上市公司。自2013年10月，他在Perma Fix Environmental Solutions公司任职。Perma Fix Environmental Solutions公司是一家上市公司，致力于解决环境问题并开展相关业务。自2012年4月至2013年4月，他在InfuSystem Holdings公司任职。InfuSystem Holdings公司是一家提供医疗设备和服务的上市公司。他在Axial Biotech公司担任总裁、首席执行官和董事。Axial Biotech公司是他于2003年1月与他人共同创办的公司。该公司是一家采用分子诊断技术以治疗脊椎病的风险投资公司。作为Axial Biotech公司的总裁和首席执行官，他把基因药学带入整形外科领域。Axial Biotech公司还开发并推广了ScoliScore，利用多基因测试方法来判定患有脊柱侧凸症状儿童的脊柱侧弯度发展的可能性。通过产品开发和国际推广手段，他引领Axial公司从开端到发展，他还筹集了3000万美元的风险资本，并和Medtronic公司、Johnson & Johnson 公司和 Smith & Nephew这三家公司确立了合作伙伴关系。在与他人建立Axial公司前，即自1997年至2003年，他在Fabian & Clendenin公司进行律师事务的实习。他在Middlebury College以优异成绩获得学士学位，并在California大学Hastings College of La获得法学博士学位。
John M. Climaco joined the company's Board of Directors in July 2017. Mr. Climaco served as the chief executive officer of CNS Pharmaceuticals, Inc. from September 2017 until December 2025. Mr. Climaco has served in leadership roles in a variety of healthcare companies. From 2014 until 2017, Mr. Climaco served as the Executive Vice ‐President of Perma‐Fix Medical S.A. From 2002 until 2012, Mr. Climaco served as President and CEO of Axial Biotech, Inc., a DNA diagnostics company. Mr. Climaco previously served as a director of Digirad, Inc., a leading national provider of imaging services; PDI, Inc., a provider of outsourced commercial services to pharma companies; InfuSystem Holdings, Inc., the largest supplier of infusion services to oncologists in the United States; and Birner Dental Management Services, Inc., a provider of practice management services to the dental industry. Mr. Climaco obtained his Juris Doctorate Degree from University of California Hastings College of Law, San Francisco, CA and a Bachelors of Philosophy from Middlebury College, Middlebury, VT. Mr. Climaco is active with the State Bar of Utah. - John M. Climaco， 他是一名法律博士，也是一位经验丰富而且成就突出的企业行政管理人员、董事和律师，并且具备15年在上市公司和私营企业任职的企业管理和企业战略经验。自2012年12月，他在Digirad 公司担任董事。自2013年12月，他在PDI公司任职。PDI公司是一家外包销售和营销的上市公司。自2013年10月，他在Perma Fix Environmental Solutions公司任职。Perma Fix Environmental Solutions公司是一家上市公司，致力于解决环境问题并开展相关业务。自2012年4月至2013年4月，他在InfuSystem Holdings公司任职。InfuSystem Holdings公司是一家提供医疗设备和服务的上市公司。他在Axial Biotech公司担任总裁、首席执行官和董事。Axial Biotech公司是他于2003年1月与他人共同创办的公司。该公司是一家采用分子诊断技术以治疗脊椎病的风险投资公司。作为Axial Biotech公司的总裁和首席执行官，他把基因药学带入整形外科领域。Axial Biotech公司还开发并推广了ScoliScore，利用多基因测试方法来判定患有脊柱侧凸症状儿童的脊柱侧弯度发展的可能性。通过产品开发和国际推广手段，他引领Axial公司从开端到发展，他还筹集了3000万美元的风险资本，并和Medtronic公司、Johnson & Johnson 公司和 Smith & Nephew这三家公司确立了合作伙伴关系。在与他人建立Axial公司前，即自1997年至2003年，他在Fabian & Clendenin公司进行律师事务的实习。他在Middlebury College以优异成绩获得学士学位，并在California大学Hastings College of La获得法学博士学位。
- John M. Climaco joined the company's Board of Directors in July 2017. Mr. Climaco served as the chief executive officer of CNS Pharmaceuticals, Inc. from September 2017 until December 2025. Mr. Climaco has served in leadership roles in a variety of healthcare companies. From 2014 until 2017, Mr. Climaco served as the Executive Vice ‐President of Perma‐Fix Medical S.A. From 2002 until 2012, Mr. Climaco served as President and CEO of Axial Biotech, Inc., a DNA diagnostics company. Mr. Climaco previously served as a director of Digirad, Inc., a leading national provider of imaging services; PDI, Inc., a provider of outsourced commercial services to pharma companies; InfuSystem Holdings, Inc., the largest supplier of infusion services to oncologists in the United States; and Birner Dental Management Services, Inc., a provider of practice management services to the dental industry. Mr. Climaco obtained his Juris Doctorate Degree from University of California Hastings College of Law, San Francisco, CA and a Bachelors of Philosophy from Middlebury College, Middlebury, VT. Mr. Climaco is active with the State Bar of Utah.
高管简历
中英对照 | 中文 | 英文- Walter V. Klemp
Walter V. Klemp，公司联合创始人，自2015年7月起担任董事会主席兼首席执行官，自2017年8月起担任总裁。Klepp先生还自2022年1月起担任Autonomix Medical，Inc.（纳斯达克：AMIX）董事会执行主席。从2018年7月到2021年12月，Klepp先生在Soliton, Inc.的董事会担任执行主席，该公司是一家医疗器械公司，专注于为Moleculin Biotech Biotech，Inc. e开发美学新技术。2021年12月，Soliton，Inc.被AbbVie，Inc.收购。2011年11月至2018年7月，Klemp先生担任Soliton的首席执行官。Klemp先生于2004年至2011年4月担任Zeno Corporation的总裁兼首席执行官，在那里他从概念到FDA批准和市场启动，开发和销售皮肤病设备和药物。从1987年到2000年，Klemp先生担任Drypers Corporation的首席执行官和董事长，该公司是一家上市的跨国消费品公司，在INC 500美国增长最快公司名单上排名第一。
Walter V. Klemp is a co founder of Moleculin Biotech, Inc., a clinical stage pharmaceutical company, and has served as its Chairman of the Board and Chief Executive Officer since July 2015 and as president since August 2017. From July 2018 until December 2021, Mr. Klemp served as Executive Chairman on the Board of Directors of Soliton, Inc., a medical device company focused on developing new technology for use in aesthetics. In December 2021 Soliton, Inc. was acquired by AbbVie, Inc. From November 2011 to July 2018, Mr. Klemp served as Chief Executive Officer of Soliton. Mr. Klemp served as President and Chief Executive Officer of Zeno Corporation from 2004 to April 2011, where he developed and marketed dermatology devices and drugs from concept through FDA approval and market launch. From 1987 to 2000, Mr. Klemp served as Chief Executive Officer and Chairman of Drypers Corporation, a publicly traded multinational consumer products company that was listed as #1 on the INC 500 List of America's Fastest Growing Companies.- Walter V. Klemp，公司联合创始人，自2015年7月起担任董事会主席兼首席执行官，自2017年8月起担任总裁。Klepp先生还自2022年1月起担任Autonomix Medical，Inc.（纳斯达克：AMIX）董事会执行主席。从2018年7月到2021年12月，Klepp先生在Soliton, Inc.的董事会担任执行主席，该公司是一家医疗器械公司，专注于为Moleculin Biotech Biotech，Inc. e开发美学新技术。2021年12月，Soliton，Inc.被AbbVie，Inc.收购。2011年11月至2018年7月，Klemp先生担任Soliton的首席执行官。Klemp先生于2004年至2011年4月担任Zeno Corporation的总裁兼首席执行官，在那里他从概念到FDA批准和市场启动，开发和销售皮肤病设备和药物。从1987年到2000年，Klemp先生担任Drypers Corporation的首席执行官和董事长，该公司是一家上市的跨国消费品公司，在INC 500美国增长最快公司名单上排名第一。
- Walter V. Klemp is a co founder of Moleculin Biotech, Inc., a clinical stage pharmaceutical company, and has served as its Chairman of the Board and Chief Executive Officer since July 2015 and as president since August 2017. From July 2018 until December 2021, Mr. Klemp served as Executive Chairman on the Board of Directors of Soliton, Inc., a medical device company focused on developing new technology for use in aesthetics. In December 2021 Soliton, Inc. was acquired by AbbVie, Inc. From November 2011 to July 2018, Mr. Klemp served as Chief Executive Officer of Soliton. Mr. Klemp served as President and Chief Executive Officer of Zeno Corporation from 2004 to April 2011, where he developed and marketed dermatology devices and drugs from concept through FDA approval and market launch. From 1987 to 2000, Mr. Klemp served as Chief Executive Officer and Chairman of Drypers Corporation, a publicly traded multinational consumer products company that was listed as #1 on the INC 500 List of America's Fastest Growing Companies.
- Donald Picker
Donald Picker，2007年加入Moleculin，担任首席执行官，自2015年7月起担任首席运营官，2016年1月起担任总裁；2007年成为IntertechBio的首席执行官；2006年至2007年间担任Tapestry Pharmaceuticals的总裁；1998年至2003年间担任Synergy Pharmaceuticals的首席执行官，该公司已与Callisto Pharmaceuticals合并，而他在后者担任研发副总裁直至2006年。他领导研发卡铂（carboplatin）和顺铂（cisplatin）从概念到通过新药审核。这些药物一通过审核便被用于首选化疗药物。他获得了Brooklyn Polytechnic University的学士学位，1975年获得SUNY Albany的博士学位。
Donald Picker has served as chief scientific officer since August 2017 after serving as chief operating officer from July 2015 until August 2017 and as president from January 2016 to August 2017. From 2006 through 2007, Dr. Picker was the President of Tapestry Pharmaceuticals. From 1998 to 2003, Dr. Picker was CEO of Synergy Pharmaceuticals. Synergy was merged into Callisto Pharmaceuticals where he was vice president of research and development until 2006. Dr. Picker led the development of carboplatin and cisplatin from concept to FDA approval. From 2018 to 2019, Dr. Picker served on the board of directors of CNS Pharmaceuticals, Inc., and Dr. Picker served as the Chief Science Officer of CNS Pharmaceuticals, Inc. on a part time basis from September 2017 until February 2026. Dr. Picker received his BS degree from Brooklyn Polytechnic University and his PhD from SUNY Albany in 1975. Dr. Picker is currently devoting only part of his work time to Moleculin Biotech, Inc. and provides services as needed to us.- Donald Picker，2007年加入Moleculin，担任首席执行官，自2015年7月起担任首席运营官，2016年1月起担任总裁；2007年成为IntertechBio的首席执行官；2006年至2007年间担任Tapestry Pharmaceuticals的总裁；1998年至2003年间担任Synergy Pharmaceuticals的首席执行官，该公司已与Callisto Pharmaceuticals合并，而他在后者担任研发副总裁直至2006年。他领导研发卡铂（carboplatin）和顺铂（cisplatin）从概念到通过新药审核。这些药物一通过审核便被用于首选化疗药物。他获得了Brooklyn Polytechnic University的学士学位，1975年获得SUNY Albany的博士学位。
- Donald Picker has served as chief scientific officer since August 2017 after serving as chief operating officer from July 2015 until August 2017 and as president from January 2016 to August 2017. From 2006 through 2007, Dr. Picker was the President of Tapestry Pharmaceuticals. From 1998 to 2003, Dr. Picker was CEO of Synergy Pharmaceuticals. Synergy was merged into Callisto Pharmaceuticals where he was vice president of research and development until 2006. Dr. Picker led the development of carboplatin and cisplatin from concept to FDA approval. From 2018 to 2019, Dr. Picker served on the board of directors of CNS Pharmaceuticals, Inc., and Dr. Picker served as the Chief Science Officer of CNS Pharmaceuticals, Inc. on a part time basis from September 2017 until February 2026. Dr. Picker received his BS degree from Brooklyn Polytechnic University and his PhD from SUNY Albany in 1975. Dr. Picker is currently devoting only part of his work time to Moleculin Biotech, Inc. and provides services as needed to us.
- Jonathan P. Foster
Jonathan P. Foster，自2016年8月起担任首席财务官兼执行副总裁。2012年2月至2016年8月，福斯特先生担任InfuSystem Holdings，Inc.的首席财务官和执行副总裁。InfuSystem Holdings，Inc.是一家为医疗保健行业提供输液泵和相关服务的全国性供应商。2011年5月至2012年1月，Foster先生在德国汉莎航空集团的子公司LSG Sky Chefs，USA，Inc.担任首席财务官的顾问。在此之前，Foster先生曾在上市公司和私营公司担任各种高级管理层职务，最初在Deloitte & Touche，LLP担任经理。Foster先生于2006年至2012年期间担任南卡罗来纳州金融机构董事会成员，并于2018年6月至2021年12月期间担任Soliton, Inc.的董事会成员，该公司是一家医疗器械公司，专注于为Moleculin Biotech，Inc. e在美学领域开发新技术，曾担任审计委员会和薪酬委员会主席以及提名与治理委员会的前任主席。2021年12月，Soliton，Inc.被AbbVie，Inc.收购。自2021年6月起，Foster先生担任在VLCN上市的电动越野车公司Volcon, Inc.的董事会成员，担任该公司前任主席和现任审计委员会成员、提名与治理委员会成员以及薪酬委员会主席。Foster先生还自2022年1月起担任Autonomix Medical，Inc.（AMIX）的董事会成员，该公司是一家在纳斯达克上市的医疗器械公司。在那里，他担任审计和薪酬委员会的主席。Foster先生是一名注册会计师（南卡罗来纳州），拥有美国注册会计师协会特许全球管理会计师的称号。
Jonathan P. Foster has served as the Chief Financial Officer and Executive Vice President of Moleculin Biotech, Inc., a clinical stage pharmaceutical company, since August 2016.From February 2012 to August 2016, Mr. Foster served as Chief Financial Officer and Executive Vice President of InfuSystem Holdings, Inc., a national provider of infusion pumps and related services to the healthcare industry. From May 2011 to January 2012, Mr. Foster served as a consultant to the Chief Financial Officer of LSG Sky Chefs, USA, Inc., a subsidiary of Deutsche Lufthansa AG. Prior to that Mr. Foster served in various C suite capacities with public and private companies with his start beginning as Manager at Deloitte & Touche, LLP. Mr. Foster served on the Board of Financial Institutions for the State of South Carolina from 2006 to 2012 and from June 2018 until December 2021 served on the Board of Directors of Soliton, Inc., a medical device company focused on developing new technology for use in aesthetics, where he was the Chairman of the Audit and Compensation Committees and the past Chairman of the Nominating & Governance Committee. In December 2021 Soliton, Inc. was acquired by AbbVie, Inc. Since June 2021, Mr. Foster has served on the Board of Directors of Empery Digital, Inc. where he is the past Chairman and current member of the Audit Committee, a member of the Nominating & Governance Committee and is the Chairman of the Compensation Committee. Mr. Foster is a Certified Public Accountant (South Carolina) and holds the designation of Chartered Global Management Accountant from the American Institute of Certified Public Accountants. He received his BS in Accounting from Clemson University in 1985.- Jonathan P. Foster，自2016年8月起担任首席财务官兼执行副总裁。2012年2月至2016年8月，福斯特先生担任InfuSystem Holdings，Inc.的首席财务官和执行副总裁。InfuSystem Holdings，Inc.是一家为医疗保健行业提供输液泵和相关服务的全国性供应商。2011年5月至2012年1月，Foster先生在德国汉莎航空集团的子公司LSG Sky Chefs，USA，Inc.担任首席财务官的顾问。在此之前，Foster先生曾在上市公司和私营公司担任各种高级管理层职务，最初在Deloitte & Touche，LLP担任经理。Foster先生于2006年至2012年期间担任南卡罗来纳州金融机构董事会成员，并于2018年6月至2021年12月期间担任Soliton, Inc.的董事会成员，该公司是一家医疗器械公司，专注于为Moleculin Biotech，Inc. e在美学领域开发新技术，曾担任审计委员会和薪酬委员会主席以及提名与治理委员会的前任主席。2021年12月，Soliton，Inc.被AbbVie，Inc.收购。自2021年6月起，Foster先生担任在VLCN上市的电动越野车公司Volcon, Inc.的董事会成员，担任该公司前任主席和现任审计委员会成员、提名与治理委员会成员以及薪酬委员会主席。Foster先生还自2022年1月起担任Autonomix Medical，Inc.（AMIX）的董事会成员，该公司是一家在纳斯达克上市的医疗器械公司。在那里，他担任审计和薪酬委员会的主席。Foster先生是一名注册会计师（南卡罗来纳州），拥有美国注册会计师协会特许全球管理会计师的称号。
- Jonathan P. Foster has served as the Chief Financial Officer and Executive Vice President of Moleculin Biotech, Inc., a clinical stage pharmaceutical company, since August 2016.From February 2012 to August 2016, Mr. Foster served as Chief Financial Officer and Executive Vice President of InfuSystem Holdings, Inc., a national provider of infusion pumps and related services to the healthcare industry. From May 2011 to January 2012, Mr. Foster served as a consultant to the Chief Financial Officer of LSG Sky Chefs, USA, Inc., a subsidiary of Deutsche Lufthansa AG. Prior to that Mr. Foster served in various C suite capacities with public and private companies with his start beginning as Manager at Deloitte & Touche, LLP. Mr. Foster served on the Board of Financial Institutions for the State of South Carolina from 2006 to 2012 and from June 2018 until December 2021 served on the Board of Directors of Soliton, Inc., a medical device company focused on developing new technology for use in aesthetics, where he was the Chairman of the Audit and Compensation Committees and the past Chairman of the Nominating & Governance Committee. In December 2021 Soliton, Inc. was acquired by AbbVie, Inc. Since June 2021, Mr. Foster has served on the Board of Directors of Empery Digital, Inc. where he is the past Chairman and current member of the Audit Committee, a member of the Nominating & Governance Committee and is the Chairman of the Compensation Committee. Mr. Foster is a Certified Public Accountant (South Carolina) and holds the designation of Chartered Global Management Accountant from the American Institute of Certified Public Accountants. He received his BS in Accounting from Clemson University in 1985.